- Home
- ABOS vs COYA Comparison
ABOS vs COYA Comparison
Compare ABOS & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.11
HOLD
Current Price
$5.46
Company Overview
Basic Information| Metric | ABOS | COYA |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 126.6M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ABOS | COYA |
|---|---|---|
| Price | $2.11 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $7.67 | ★ $15.80 |
| AVG Volume (30 Days) | 154.4K | ★ 197.2K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,987,706.00 |
| Revenue This Year | N/A | $69.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $4.65 |
| 52 Week High | $2.46 | $8.29 |
Technical Indicators
Market Signals| Indicator | ABOS | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.67 | 40.36 |
| Support Level | $2.01 | $5.25 |
| Resistance Level | $2.39 | $5.77 |
| Average True Range (ATR) | 0.13 | 0.34 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 50.93 | 17.66 |
Price Performance
Historical Comparison ABOS
COYA
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.